ABO and Rh Blood Groups and Risk of Colorectal Adenocarcinoma

Background: Previous studies have observed an association between ABO blood group and risk for certaingastrointestinal malignancies, including pancreatic and gastric cancer. However, it is unclear whether thereis such an association with colorectal cancer (CRC). In this study, possible relationships between ABO bloodgroups and Rh factor and KRAS status in patients with CRC were investigated. Materials and Methods: In 1,620patients with CRC, blood group and Rh factor were examined and compared with the control group of 3,022,883healthy volunteer blood donors of the Turkish Red Crescent between 2004 and 2011. The relationship of bloodgroups with wild type K-ras status was also evaluated. Results: Overall distributions of ABO blood groups aswell as Rh factor were comparable between patients (45% A, 7.2% AB, 16.4% B, 31.4% O, and 87.2% Rh+) andcontrols (42.2% A, 7.6% AB, 16.3% B, 33.9% O, and 87.7% Rh+) (p=0.099). However, there were statisticallysignificant difference between patients and controls with respect to O vs. non O blood group (p=0.033) andmarginally significant difference for A vs. non-A blood group (p=0.052). Among patients, the median age was62 (range 17-97), 58.1% were male. There were no statistically significant differences respect to sex and K-rasstatus. Conclusion: In present study, the ABO/Rh blood groups were statistically significantly associated withthe risk of CRC. There were no relationship between K-ras status and ABO blood group and Rh factor. Howeverfurther studies with larger numbers of patients are needed to establish the role of blood groups and to definet he mechanisms by which ABO blood type affect CRC.     

Prognostic value of ABO blood group in southern Chinese patients with established nasopharyngeal carcinoma

Background:

ABO blood group is associated with aetiology of nasopharyngeal carcinoma (NPC); however, the effect of it on survival of patients diagnosed with NPC has not been explored.

Methods:

We retrospectively analysed two cohorts of southern Chinese patients with WHO histological type III: intensity-modulated radiotherapy (IMRT) cohort, 924 patients; and conventional radiotherapy (CRT) cohort, 1193 patients. Associations of ABO blood group with survival were estimated using Cox regression.

Results:

In IMRT cohort, we observed significant associations of blood type A with overall survival (OS) and distant metastasis-free survival (DMFS), compared with type O, after adjusting for prognostic factors. Compared with non-A blood types (B, AB, and O), type A patients had significantly lower OS and DMFS (adjusted hazard ratio (HR)=1.49, 95% CI 1.03–2.17, P=0.036; HR=1.68, 95% CI 1.13–2.51, P=0.011, respectively); similar results were obtained in CRT cohort. Subgroup analyses of the entire population showed that lower OS conferred by blood type A was not significantly modified by age, smoking status, drinking status, immunoglobulin A against Epstein–Barr virus viral capsid antigen (VCA-IgA) titre, or chemotherapy; however, lower OS was not observed in female patients or patients with early clinical stage disease.

Conclusion:

ABO blood group is associated with survival in NPC; patients with blood type A had significantly lower OS and DMFS than patients with non-A blood types.     

ABO blood group and nasopharyngeal carcinoma risk in a population of Southeast China

Previous studies found that the ABO blood type alters the individual susceptibility of some malignancies. However, whether such an association exists between ABO blood type and nasopharyngeal carcinoma (NPC) remains unknown. A case‐control study was conducted, with 1,538 patients who had NPC and 1,260 cancer‐free controls. The association between ABO blood type and NPC incidence was evaluated using unconditional logistic regression analysis. Compared with subjects with blood type O, a relatively higher risk was observed among cases with blood types A or AB, with ORs (95% confidence interval) of 1.287 (1.072 − 1.545), p = 0.007 and 1.390 (1.007 − 1.919), p = 0.045, respectively, after adjusting for gender, age, smoking status and family history of cancer. The rate of distant metastasis was significantly higher among male patients with blood type A than in patients with non‐A blood types (6.8 vs. 3.5%, p = 0.027). Our results suggest that blood types A or AB is associated with an increased risk of NPC. Further studies are needed to confirm this association and to explore the mechanisms involved.     

ABO Blood Groups are Not Associated with Treatment Response and Prognosis in Patients with Local Advanced Non-Small Cell Lung Cancer

Background: Lung cancer is the leading cause of cancer death, late diagnosis being the main obstacle toimproving the outcomes with stage at diagnosis as an important prognostic factor. Relationships betweenABO blood groups and risk of benign or malignant diseases have been observed and in this study, we aimedto investigate whether they might affect prognosis and response to chemoradiotherapy in patients with localadvanced non-small cell lung cancer (NSCLC). Materials and Methods: Eighty-one patients with non-metastaticlocal advanced NSCLC were included in the study. ABO blood groups were A in 45 (55.6%), B in 7 (8.6%), ABin 8 (9.9%), and O in 21 (25.9%) patients. The patients were also divided two groups according to blood group A(45 patients) and non-A (B, AB and O; 36 patients). Response to chemoradiotherapy was complete remission in10 (12.3%), disease regression in 42 (51.9%), stable disease in 12 (14.8%), and disease progression in 17 (21.0%)patients. Results: There was no significant difference among ABO blood group categories or between patientswith A blood group and those with non-A blood group in terms of responses to chemoradiotherapy (p>0.05).There were also no significant differences regarding overall and disease-free survival rates. Conclusion: TheABO blood group system has no significant effect on prognosis and response to chemoradiotherapy in patientswith non-metastatic NSCLC.     

A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China

Little is known about the relationship between ABO blood groups and the clinicopathologic features in gastric adenocarcinoma patients of China. Whether the distribution of ABO blood groups in patients with gastric adenocarcinoma differs from that with benign diseases is also unknown. A total of 474 gastric adenocarcinoma patients and 404 with benign diseases were enrolled for the study. The relationship between patients' ABO blood groups and the clinicopathologic features was analyzed. The percentage of blood group AB was more common in men of gastric cancer than in benign diseases. The proportion of angiolymphatic invasion among patients with blood group O was significantly lower than those with other blood groups (P = 0.034). Proportion of tumors associated with estrogen receptor (ER), progestogen receptor (PR) and carcinoembryonic antigen (CEA) expression in blood type A was significantly higher than in other blood types (P = 0.002 for ER expression, 0.009 for PR expression, 0.003 for CEA expression). Proportion of tumors associated with serum CEA and CA19-9 elevation in blood type AB was significantly lower than in other blood types (P < 0.001 for serum CEA elevation, 0.005 for CA19-9 elevation). Though there was no significant difference between ABO blood groups and survival of the patients, patients with blood group B had a trend to show superiority in the survival. The significance of ABO blood group distribution might be associated with biological behavior of gastric adenocarcinoma patients. However, it was found not to be a prognosis factor for patients with gastric adenocarcinoma.     

Prognostic value of ABO blood types in young patients with breast cancer; a nationwide study in Korean Breast Cancer Society

The purpose of this study was to investigate the relationship between ABO blood types and breast cancer survival in young Korean patients. This was a retrospective study of 115,474 patients who were surgically treated for primary breast cancer between 1987 and 2011 in Korea. All data were collected by the Korean Breast Cancer Society (KBCS) online breast cancer registry. Each hospital serologically examined the ABO blood types of patients before surgery. There was no significant difference in overall survival (OS) or breast cancer-specific survival (BCSS) among ABO blood types. Type of surgery; T stage; N stage; histologic grade; status of estrogen receptor, progesterone receptor, and HER2; and chemotherapy were significant prognostic factors of OS and BCSS in univariate analysis and multivariate analyses. Compared to women with blood type O, there was a difference in OS and BCSS for blood type A, blood type B, or blood type AB. Compared to blood group non-O, patients with blood group O were more likely to have favorable prognosis when younger than 40 years. Further follow-up studies are necessary to clarify the role of the impact of ABO blood types on prognosis of breast cancer.     

The ABO blood group predicts survival in esophageal squamous cell carcinoma in patients who ever smoked: a retrospective study from China

The association between clinical characteristics, prognosis, and the ABO blood group of esophageal squamous cell carcinoma (ESCC) is rarely discussed. The aims of the current study were to investigate the correlation of the ABO blood group with the clinicopathological characteristics in a consecutive cohort of patients with ESCC and to assess whether the ABO blood group was associated with prognosis. A total of 511 patients with locoregional ESCC who underwent curative treatment were retrospectively analyzed at a single institution between January 2007 and December 2008. The relationship between the ABO blood group and clinicopathological variables was assessed by chi-squared analysis. The Kaplan-Meier method was used to estimate the 5-year overall survival (OS). The Cox proportional hazards model was used in univariate and multivariate analyses of OS. There were no significant differences in the clinicopathological characteristics among patients with different ABO blood groups. The 5-year OS rates were 50.0 % for patients with blood type A, 45.4 % for type B, 50.8 % for type O, and 60.7 % for type AB. In a subgroup analysis of 321 patients who ever smoked, the B/O group had a poorer OS compared with the A/AB group (p?=?0.0245). Multivariate analysis revealed an unfavorable and independent impact of the B/O group on patient survival with ESCC who ever smoked (p?=?0.011). Findings suggest the B/O blood type as a predictor of mortality in ESCC patients who ever smoked. Future studies conducted prospectively are warranted to confirm this work and to better understand the underlying biological mechanisms.     

ABO blood group is a predictor of survival in patients with laryngeal cancer

Background:Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown. The purpose of this study was to investigate the association between the ABO blood group and clinico?pathologic characteristics of patients with laryngeal cancer and assess whether the ABO blood group was associated with prognosis. Methods:We analyzed the records of 1260 patients with laryngeal cancer who underwent curative treatment at Sun Yat?sen University Cancer Center between January 1993 and December 2009. The Chi?square test was used to assess the relationship between the ABO blood group and clinicopathologic characteristics. The Kaplan–Meier method was used to estimate 3?, 5?, and 10?year overall survival (OS) rates. The Cox proportional hazards model was used in univariate and multivariate analyses of OS. Results:No signiifcant association was found between the ABO blood group and clinicopathologic characteristics except for primary tumor site. The median OS for patients with blood groups A, B, AB, and O were 87.0, 80.0, 90.0, and 72.5months, respectively. The 3?, 5?, and 10?year OS rates were 82.4%, 76.0%, and 67.5% for patients with blood group A; 77.4%, 69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 65.6% for patients with blood group AB; and 71.7%, 66.4%, and 55.5% for patients with blood group O, respectively. Univariate and multivariate analyses showed that the ABO blood group had signiifcant effects on prognosis in patients with laryngeal cancer. Conclusions:The ABO blood group is associated with survival in patients with laryngeal cancer. Patients with blood group O had signiifcantly shorter OS than patients with other ABO blood groups.     

AB0 blood group and prognosis in patients with pancreatic cancer

ABSTRACT: OBJECTIVES: Although blood group 0 is associated with a reduced risk of pancreatic cancer, little is known about the role of AB0 blood group antigens in disease progression. We assessed the prognostic relevance of AB0 blood status in a large cohort of patients with resected pancreatic cancer. METHOD: S: A total of 627 patients, who underwent resection for pancreatic ductal adenocarcinoma between October 2001 and December 2008 were enrolled. The relationship between AB0 blood group status and outcome was analyzed using univariate and multivariate Cox regression analyses. RESULTS: : In patients with pancreatic cancer the incidence of blood group 0 (31%) was lower compared to 13.044 patients without pancreatic cancer (38%) (p = 0.0005). There were no significant differences in clinicopathologic characteristics among patients with different AB0 blood groups. The 3-year and 5-year overall survival rates were 29% and 14%. On univariate analysis AB0 blood group status did not correlate with survival (p = 0.39). Multivariate analysis, however, revealed a favorable and independent impact of blood group 0 on survival (Hazard ratio 0.78; 95% confidence interval 0.62 - 0.99; p = 0.037). CONCLUSION: AB0 blood group status is associated independently with the prognosis of patients with resected pancreatic cancer.     

A relationship between ABO blood groups and clinicopathologic characteristics of patients with gastric adenocarcinoma in China

Little is known about the relationship between ABO blood groups and the clinicopathologic features in gastric adenocarcinoma patients of China. Whether the distribution of ABO blood groups in patients with gastric adenocarcinoma differs from that with benign diseases is also unknown. A total of 474 gastric adenocarcinoma patients and 404 with benign diseases were enrolled for the study. The relationship between patients’ ABO blood groups and the clinicopathologic features was analyzed. The percentage of blood group AB was more common in men of gastric cancer than in benign diseases. The proportion of angiolymphatic invasion among patients with blood group O was significantly lower than those with other blood groups (P = 0.034). Proportion of tumors associated with estrogen receptor (ER), progestogen receptor (PR) and carcinoembryonic antigen (CEA) expression in blood type A was significantly higher than in other blood types (P = 0.002 for ER expression, 0.009 for PR expression, 0.003 for CEA expression). Proportion of tumors associated with serum CEA and CA19-9 elevation in blood type AB was significantly lower than in other blood types (P < 0.001 for serum CEA elevation, 0.005 for CA19-9 elevation). Though there was no significant difference between ABO blood groups and survival of the patients, patients with blood group B had a trend to show superiority in the survival. The significance of ABO blood group distribution might be associated with biological behavior of gastric adenocarcinoma patients. However, it was found not to be a prognosis factor for patients with gastric adenocarcinoma.

     

Is There an Association between Blood Group and Survival in Pancreatic Cancer?

Background: An association between the ABO groups and pancreatic cancer has been shown previously,group A being significantly commoner in affected patients. We conducted the present study to investigate theprognostic effect of ABO blood group on overall survival of pancreas cancer patients. Methods: Patients whowere diagnosed between 2005 and 2010 with pancreas cancer at Ankara Numune Education and ResearchHospital were analyzed retrospectively. Patient demographics and ABO blood groups were obtained from medicalcharts. Results: Fifty pancreas cancer patients with known ABO blood group were included, 26 (52%) groupA, 12 patients (24%) group 0, 9 (18%) group B, and 3 (6%) group AB. Blood group A pancreas cancer patientmedian age was 61.5 (39-80) years, with the median age of the other blood groups (B, AB,O) being 55.5 (32-74)years (p=0.14). 18% of patients with blood group A and11%of the other blood group patients had metastasis(p=0.17) at the time of diagnosis. The median overall survival of blood group A pancreas patients was significantlylower than the other blood group patients, 7.6 (95%CI: 5.0-10.2) months versus 29.0 (95%CI: 0.0-68.8) months(p=0.05). Conclusions: Acccording to previously published cohort studies a relation may exist between ABOblood groups and cancer of pancreas. In this study we observed that pancreas cancer patients with blood groupA have significantly worse overall survival than other blood groups.     

Factors Associated with Helicobacter Pylori Infection,Results from a Developing Country-Pakistan

Background: It is known that blood group antigens are related to the development of peptic ulcer andgastric carcinoma. Infections due to H. pylori are most widespread among the developing regions due to poorstandard of public health. This study sought to determine the association of H. pylori with ABO blood groups,age, gender, and smoking status among inpatients at a public sector hospital in Karachi. Materials and Methods:A cross-sectional study was conducted at endoscopy suite at a public sector hospital in Karachi in the year 2011.All the symptomatic patients coming for upper GIT endoscopy were included in this study. Results: Biopsy forhistopathology was taken from 93 patients, with an age range from 15-65 years. Age group of 15 to 20 years wasfound to be associated with H. pylori infection but without significance (p-value 0.83). In all, 36 (38.7%) turnedout to be H. pylori positive with a significant male preponderance (p=0.04). Distribution of ABO blood groups inH. pylori positive group were A=31.4%, B=15.4%, AB=25.0% and O=53.7%, with a statistically significant linkfor blood group O (p=0.05) . Rhesus factor was also compared but significant relationship was evident (p-value0.73). Conclusions: This study demonstrated that H. pylori infection can be related to ABO blood group, middleage persons and male gender. People of blood group O are more prone to develop infection related gastritis,ulcers, and even perforations, so they should be more cautious against transmission of the bacterium.     

结直肠癌发病风险与ABO血型分布的关系

目的:探讨结直肠癌患病风险与ABO血型分布的关系。方法:通过LinkDoc数据库（LinkDoc Data）抽取辽宁省肿瘤医院含有ABO血型信息的结直肠癌住院患者的数据2 333例,与本地区另一家三甲医院的血型样本（36 124例）对照,回顾性分析不同血型患结直肠癌的风险。结果:2 333例结直肠癌患者中,A型患者663例（28.42%）,AB型患者689例（29.53%）,B型患者721例（30.90%）,O型患者260例（11.14%）。与对照组比较,AB型较非AB型结直肠癌患病风险升高（OR=3.54,95%CI=3.219~3.893）,O型较非O型结直肠癌患病风险下降（OR=0.299,95%CI=0.262~0.341）。结论:结直肠癌患者ABO血型分布与对照人群ABO血型分布有明显差别,AB型人群较其它血型人群结直肠癌发生风险升高,而O型结直肠癌发生风险降低,血型可能是结直肠癌发生的危险因素之一,但是有地域差别,在本地区AB血型人群应该是结直肠癌重点筛查对象。     

ABO Blood Group Differentials on Survival in Hepatocellular Carcinoma Patients Treated with Chemoembolization

Background: The association between ABO blood group and the prognosis of hepatocellular carcinoma (HCC) remains unclear. We investigated the impact of ABO blood groups as a prognostic factor in HCC patients treated with transarterial chemoembolization (TACE). Materials and methods: We revisited records of all HCC patients who underwent TACE between January 2007 and December 2019 at a tertiary care hospital. The inclusion criteria were HCC patients, Child-Pugh score A5-B7, and treated with TACE monotherapy. The baseline characteristics of each patient were compared against their blood group and the survival analysis was carried out using Cox’s regression. With Bonferroni adjustment for multiple comparisons, P-values <.0125 were considered statistically significant. Results: Of 211 eligible patients, the frequencies of blood groups O, A, B, and AB were 89, 54, 56, and 12, respectively. Their respective months of median survival were 41, 20, 21, and 42. After adjustments in the six-and-twelve criteria and Child-Pugh scores, and using blood group O as the referent group, the coefficients (SE) of groups A, B, and AB were 0.69 (0.24), 0.47 (0.23), and 0.49 (0.49), respectively. A significant difference in survival was found only between patients with blood group O vs A (hazard ratio, 2.00; confidence interval, 1.25-3.21). Conclusions: ABO blood group is associated with the prognosis of HCC patients treated with TACE monotherapy. In our data, patients with blood group O tended to have the best survival. However, only blood group A patients had a significantly shorter survival rate comparing to blood group O.     

ABO血型与HBV相关性肝细胞癌患者肝切除术后预后的关联研究

目的 分析ABO血型与乙型肝炎病毒(HBV)相关性肝细胞癌(hepatocellular carcinoma,HCC)患者临床病理特征的相关性,并探讨其与HCC肝切除术后预后的关联.方法 回顾性分析2014年1月1日至2017年12月31日于广西医科大学附属肿瘤医院首诊且行肝癌肝切除术并获随访的888例HBV相关性HC...     

Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type

BACKGROUND: Patients with International Union Against Cancer (UICC) Stage I-II nasopharyngeal carcinoma (NPC) appear to have a relatively favorable prognosis and generally are excluded from trials of combined modality treatment. More recently, plasma/serum cell-free Epstein-Barr virus (EBV) DNA has been shown to be measurable in the majority of NPC patients at the time of diagnosis, and appears to have prognostic significance. However, within Stage I-II disease, in which failure events are infrequent, the prognostic impact of the pretreatment EBV DNA level has not been addressed to our knowledge. This issue has management implications because different therapeutic strategies currently are employed for patients with good-risk and those with poor-risk NPC. METHODS: A cohort of 90 patients with UICC Stage I-II NPC (World Health Organization Grade 2/3 histology) had their pretherapy plasma/serum EBV DNA levels determined by a quantitative polymerase chain reaction assay and correlated with the probability of posttherapy failure. All patients received radiation therapy only, except for three patients who also received concurrent chemotherapy. Kaplan-Meier plots of the probability of locoregional failure, distant failure, and cancer-specific survival were compared with reference to clinical stage and EBV DNA levels. RESULTS: With a median follow-up time of 45 months, 12 patients and 7 patients, respectively, had developed locoregional and distant failures, including 2 patients with both local and distant failures. Patients with distant failure had significantly higher pretherapy EBV DNA levels than those without failure (a median of 13,219 copies/mL [interquatile-range, 274,635 copies/mL] vs. a median of 423 copies/mL [interquatile-range, 2753 copies/mL]). The probability of distant failure was significantly higher in patients with high (>4000 copies/mL plasma) compared with low EBV DNA levels (P=0.0001, log-rank test) and for Stage IIB disease compared with Stage I and Stage IIA disease combined (P=0.0149, log-rank test), but was not significantly different between patients with Stage II and those with Stage I disease. The risks of locoregional failure were not significantly different between patients with high and those with low EBV DNA levels, and also was not significantly different between clinical substages. Approximately 35% of patients with Stage IIB disease were in the at-risk group for distant failure, as identified by high EBV DNA levels. CONCLUSIONS: Within a group of patients with UICC Stage I-II NPC, the pretherapy plasma EBV DNA level was found to identify a poor-risk group with a probability of distant failure similar to that of patients with advanced stage disease. This group of patients may warrant management considerations currently applicable only to cases of Stage III-IV disease. The prognostic significance of designating Stage IIB disease as per the 1997 UICC staging was confirmed, although the pretherapy EBV DNA level appears to be a more powerful prognostic discriminator in patients with early-stage NPC.     

Prognostic role of ABO blood type in patients with extranodal natural killer/T cell lymphoma,nasal type: a triple-center study

Background:The prognostic significance of ABO blood type for lymphoma is largely unknown.We evaluated the prognostic role of ABO blood type in patients with extranodal natural killer (NK)/T-cell lymphoma (ENKTL).Methods:We retrospectively analyzed clinical data of 697 patients with newly diagnosed ENKTL from three cancer centers.The prognostic value of ABO blood type was evaluated using Kaplan-Meier curves and Cox proportional hazard models.The prognostic values of the International Prognostic Index (IPI) and the Korean Prognostic Index (KPI) were also evaluated.Results:Compared with patients with blood type O,those with blood type non-O tended to display elevated baseline serum C-reactive protein levels (P =0.038),lower rate of complete remission (P =0.005),shorter progression-free survival (PFS,P ＜ 0.001),and shorter overall survival (OS,P =0.001).Patients with blood type O/AB had longer PFS (P ＜ 0.001) and OS (P =0.001) compared with those with blood type A/B.Multivariate analysis demonstrated that age ＞60 years (P ＜ 0.001),mass ＞5 cm (P =0.001),stage Ⅲ/Ⅳ (P ＜ 0.001),elevated serum lactate dehydrogenase (LDH) levels (P =0.001),and blood type non-O were independent adverse predictors of OS (P =0.001).ABO blood type was found to be superior to both the IPI in discriminating patients with different outcomes in the IPI low-risk group and the KPI in distinguishing between the intermediate-to-low-and high-to-intermediate-risk groups.Conclusions:ABO blood type was an independent predictor of clinical outcome for patients with ENKTL.     

Relationships between Skin Cancers and Blood Groups - Link between Non-melanomas and ABO/Rh Factors

Background: This investigation focused on possible relationships between skin cancers and ABO/Rh bloodgroups. Materials and Methods: Between January 2005 and December 2012, medical data of 255 patients withskin cancers who were admitted to Kayseri Training and Research Hospital, Radiation Oncology and PlasticSurgery Outpatient Clinics were retrospectively analyzed. Blood groups of these patients were recorded. Thecontrol group consisted of 25701 healthy volunteers who were admitted to Kayseri Training and ResearchHospital, Blood Donation Center between January 2010 and December 2011. The distribution of the blood groupsof the patients with skin cancers was compared to the distribution of ABO/Rh blood groups of healthy controls.The association of the histopathological subtypes of skin cancer with the blood groups was also investigated.Results: Of the patients, 50.2% had A type, 26.3% had O type, 16.1% had B type, and 7.5% had AB blood groupwith a positive Rh (+) in 77.3%. Of the controls, 44.3% had A type, 31.5% had 0 type, 16.1% had B type, and8.1% had AB blood group with a positive Rh (+) in 87.8%. There was a statistically significant difference in thedistribution of blood groups and Rh factors (A Rh (-) and 0 Rh positive) between the patients and controls. A totalof 36.8% and 20.4% of the patients with basal cell carcinoma (BCC) had A Rh (+) and B Rh (+), respectively,while 39.2% and 27.6% of the controls had A Rh (+) and B Rh (+), respectively. A significant relationship wasobserved between the patients with BCC and controls in terms of A Rh (-) (p=0.001). Conclusion: Our studyresults demonstrated that there is a significant relationship between non-melanoma skin cancer and ABO/Rhfactors.     

Association of ABO Blood Group and Risk of Lung Cancer in a Multicenter Study in Turkey

Background: The ABO blood groups and Rh factor may affect the risk of lung cancer. Materials and Methods:We analyzed 2,044 lung cancer patients with serologically confirmed ABO/Rh blood group. A group of 3,022,883healthy blood donors of Turkish Red Crescent was identified as a control group. We compared the distributionsof ABO/Rh blood group between them. Results: The median age was 62 years (range: 17-90). There was a clearmale predominance (84% vs. 16%). Overall distributions of ABO blood groups were significantly differentbetween patients and controls (p=0.01). There were also significant differences between patients and controls withrespect to Rh positive vs. Rh negative (p=0.04) and O vs. non-O (p=0.002). There were no statistically significantdifferences of blood groups with respect to sex, age, or histology. Conclusions: In the study population, ABOblood types were associated with the lung cancer. Having non-O blood type and Rh-negative feature increasedthe risk of lung cancer. However, further prospective studies are necessary to define the mechanisms by whichABO blood type may influence the lung cancer risk.     

Complement Receptor 1 Expression in Peripheral Blood Mononuclear Cells and the Association with Clinicopathological Features And Prognosis of Nasopharyngeal Carcinoma

Purpose: Complement receptor 1 (CR1) is induced by Epstein-Barr virus (EBV) and may be a potentialbiomarker of nasopharyngeal carcinoma (NPC). We conducted the present study to evaluate the association ofCR1 expression with clinicopathological features and prognosis of NPC. Methods: We enrolled 145 NPC patientsand 110 controls. Expression levels of CR1 in peripheral blood mononuclear cells (PBMCs) were detected usingquantitative real-time PCR and associations with clinicopathological features and prognosis were examined.Results: CR1 levels in the NPC group [3.54 (3.34, 3.79)] were slightly higher than those in the controls [3.33(3.20, 3.47)] (P<0.001). Increased CR1 expression was associated with histology classification (type III vs. typeII, P=0.002), advanced clinical stage (P=0.003), high T stage (P=0.017), and poor overall survival (HR, 4.89; 95%CI, 1.23-19.42; P=0.024). However, there were no statistically significant differences in CR1 expression amongN or M stages. Conclusion: These findings indicate that CR1 expression in PBMCs may be a new biomarker forprognosis of NPC and a potential therapeutic target.